These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

777 related articles for article (PubMed ID: 11836283)

  • 1. Effects of testosterone plus medroxyprogesterone acetate on semen quality, reproductive hormones, and germ cell populations in normal young men.
    McLachlan RI; O'Donnell L; Stanton PG; Balourdos G; Frydenberg M; de Kretser DM; Robertson DM
    J Clin Endocrinol Metab; 2002 Feb; 87(2):546-56. PubMed ID: 11836283
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Comparison between testosterone enanthate-induced azoospermia and oligozoospermia in a male contraceptive study. I: Plasma luteinizing hormone, follicle stimulating hormone, testosterone, estradiol, and inhibin concentrations.
    Wallace EM; Gow SM; Wu FC
    J Clin Endocrinol Metab; 1993 Jul; 77(1):290-3. PubMed ID: 8325955
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Establishing the minimum effective dose and additive effects of depot progestin in suppression of human spermatogenesis by a testosterone depot.
    Handelsman DJ; Conway AJ; Howe CJ; Turner L; Mackey MA
    J Clin Endocrinol Metab; 1996 Nov; 81(11):4113-21. PubMed ID: 8923869
    [TBL] [Abstract][Full Text] [Related]  

  • 4. The relative roles of follicle-stimulating hormone and luteinizing hormone in maintaining spermatogonial maturation and spermiation in normal men.
    Matthiesson KL; McLachlan RI; O'Donnell L; Frydenberg M; Robertson DM; Stanton PG; Meachem SJ
    J Clin Endocrinol Metab; 2006 Oct; 91(10):3962-9. PubMed ID: 16895950
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Stereological evaluation of human spermatogenesis after suppression by testosterone treatment: heterogeneous pattern of spermatogenic impairment.
    Zhengwei Y; Wreford NG; Royce P; de Kretser DM; McLachlan RI
    J Clin Endocrinol Metab; 1998 Apr; 83(4):1284-91. PubMed ID: 9543157
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Levonorgestrel implants (Norplant II) for male contraception clinical trials: combination with transdermal and injectable testosterone.
    Gonzalo IT; Swerdloff RS; Nelson AL; Clevenger B; Garcia R; Berman N; Wang C
    J Clin Endocrinol Metab; 2002 Aug; 87(8):3562-72. PubMed ID: 12161475
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Novel male hormonal contraceptive combinations: the hormonal and spermatogenic effects of testosterone and levonorgestrel combined with a 5alpha-reductase inhibitor or gonadotropin-releasing hormone antagonist.
    Matthiesson KL; Amory JK; Berger R; Ugoni A; McLachlan RI; Bremner WJ
    J Clin Endocrinol Metab; 2005 Jan; 90(1):91-7. PubMed ID: 15509637
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Testicular function in a birth cohort of young men.
    Hart RJ; Doherty DA; McLachlan RI; Walls ML; Keelan JA; Dickinson JE; Skakkebaek NE; Norman RJ; Handelsman DJ
    Hum Reprod; 2015 Dec; 30(12):2713-24. PubMed ID: 26409015
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Effects of chronic testosterone administration in normal men: safety and efficacy of high dosage testosterone and parallel dose-dependent suppression of luteinizing hormone, follicle-stimulating hormone, and sperm production.
    Matsumoto AM
    J Clin Endocrinol Metab; 1990 Jan; 70(1):282-7. PubMed ID: 2104626
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Effects of testosterone and levonorgestrel combined with a 5alpha-reductase inhibitor or gonadotropin-releasing hormone antagonist on spermatogenesis and intratesticular steroid levels in normal men.
    Matthiesson KL; Stanton PG; O'Donnell L; Meachem SJ; Amory JK; Berger R; Bremner WJ; McLachlan RI
    J Clin Endocrinol Metab; 2005 Oct; 90(10):5647-55. PubMed ID: 16030154
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Reversible azoospermia induced by an androgen-progestin combination regimen in Indonesian men.
    Pangkahila W
    Int J Androl; 1991 Aug; 14(4):248-56. PubMed ID: 1831798
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Comparison between testosterone enanthate-induced azoospermia and oligozoospermia in a male contraceptive study. III. Higher 5 alpha-reductase activity in oligozoospermic men administered supraphysiological doses of testosterone.
    Anderson RA; Wallace AM; Wu FC
    J Clin Endocrinol Metab; 1996 Mar; 81(3):902-8. PubMed ID: 8772548
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Potential of testosterone buciclate for male contraception: endocrine differences between responders and nonresponders.
    Behre HM; Baus S; Kliesch S; Keck C; Simoni M; Nieschlag E
    J Clin Endocrinol Metab; 1995 Aug; 80(8):2394-403. PubMed ID: 7543113
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Suppression of spermatogenesis in man induced by Nal-Glu gonadotropin releasing hormone antagonist and testosterone enanthate (TE) is maintained by TE alone.
    Swerdloff RS; Bagatell CJ; Wang C; Anawalt BD; Berman N; Steiner B; Bremner WJ
    J Clin Endocrinol Metab; 1998 Oct; 83(10):3527-33. PubMed ID: 9768659
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Variability in sperm suppression during testosterone administration to adult monkeys is related to follicle stimulating hormone suppression and not to intratesticular androgens.
    Narula A; Gu YQ; O'Donnell L; Stanton PG; Robertson DM; McLachlan RI; Bremner WJ
    J Clin Endocrinol Metab; 2002 Jul; 87(7):3399-406. PubMed ID: 12107257
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Induction of azoospermia in normal men with combined Nal-Glu gonadotropin-releasing hormone antagonist and testosterone enanthate.
    Tom L; Bhasin S; Salameh W; Steiner B; Peterson M; Sokol RZ; Rivier J; Vale W; Swerdloff RS
    J Clin Endocrinol Metab; 1992 Aug; 75(2):476-83. PubMed ID: 1639948
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Comparison between testosterone enanthate-induced azoospermia and oligozoospermia in a male contraceptive study. II. Pharmacokinetics and pharmacodynamics of once weekly administration of testosterone enanthate.
    Anderson RA; Wu FC
    J Clin Endocrinol Metab; 1996 Mar; 81(3):896-901. PubMed ID: 8772547
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Depot gonadotropin-releasing hormone agonist blunts the androgen-induced suppression of spermatogenesis in a clinical trial of male contraception.
    Behre HM; Nashan D; Hubert W; Nieschlag E
    J Clin Endocrinol Metab; 1992 Jan; 74(1):84-90. PubMed ID: 1727833
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Relationship between serum gonadotropins and spermatogenic suppression in men undergoing steroidal contraceptive treatment.
    McLachlan RI; Robertson DM; Pruysers E; Ugoni A; Matsumoto AM; Anawalt BD; Bremner WJ; Meriggiola C
    J Clin Endocrinol Metab; 2004 Jan; 89(1):142-9. PubMed ID: 14715841
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Testosterone undecanoate maintains spermatogenic suppression induced by cyproterone acetate plus testosterone undecanoate in normal men.
    Meriggiola MC; Costantino A; Cerpolini S; Bremner WJ; Huebler D; Morselli-Labate AM; Kirsch B; Bertaccini A; Pelusi C; Pelusi G
    J Clin Endocrinol Metab; 2003 Dec; 88(12):5818-26. PubMed ID: 14671175
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 39.